BioPharmSignal logoBioPharmSignal

Biotech News

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

Tempest Therapeutics (TPST)Tempest TherapeuticsPartnership

-Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year -Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate is in Phase 1 dose escalation for relapsed/refractory multiple myeloma -Early

Related news

TPSTTempest Therapeutics2026-10-14 12:00 EST

Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

REGNRegeneron Pharmaceuticals2026-10-01 05:00 EST

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

SNYSanofi2026-10-01 05:00 EST

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

SNYSanofi2026-10-01 05:00 EST

Communiqué de presse : Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée

KURAKura Oncology2026-11-04 14:02 EST

Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026

CHRSCoherus BioSciences, Inc.2026-10-28 20:05 EST

Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development

GERNGeron2026-10-28 12:00 EST

Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

View all latest news

Tempest Therapeutics

In Vivo CAR T Company Tempest Therapeutics develops next-generation CAR T therapies for autoimmune diseases and cancer. Its platform is designed to generate therapeutic CAR T cells directly inside the body using targeted mRNA and lipid nanoparticles. CD7-Targeted Delivery Tempest's proprietary delivery system targets CD7-positive T cells...

Recent company news

TPSTTempest Therapeutics2026-10-14 12:00 EST

Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

TPSTTempest Therapeutics2026-09-23 12:00 EST

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

TPSTTempest Therapeutics2026-09-15 20:05 EST

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

TPSTTempest Therapeutics2026-09-11 12:00 EST

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

TPSTTempest Therapeutics2026-09-08 12:30 EST

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Stock data

Close
0.38 USD
Market cap
19.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States